Anaveon is a developing IL-2 complexes which selectively promote effector T cell functions.
Anaveon has raised $119.7M in total funding. The most recent round was Series B. The last funding was announced in December 2021.
Anaveon's investors include Forbion Capital Partners, Pfizer Venture Investments, Cowen Healthcare Investments, Pontifax, Novartis Venture Fund.
Anaveon is headquartered in Bottmingen, Switzerland.
Anaveon is a developing IL-2 complexes which selectively promote effector T cell functions.
Anaveon is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Anaveon — Funding & Investors." VCBacked, December 16, 2021, https://www.vcbacked.co/company/anaveon. Accessed August 15, 2026.
VCBacked. (2021). Anaveon — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/anaveon
{{cite web |title=Anaveon — Funding & Investors |url=https://www.vcbacked.co/company/anaveon |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated